Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 193

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Phase II study of sunitinib as second-line treatment for advanced gastric cancer

Open access
Bang, Yung-Jue, Kang, Yoon-Koo, Kang, Won K., Boku, Narikazu, Chung, Hyun C., Chen, Jen-Shi, Doi, Toshihiko, Sun, Yan, Shen, Lin, Qin, Shukui, Ng, Wai-Tong, Tursi, Jennifer M., Lechuga, Maria J., Lu, Dongrui Ray, Ruiz-Garcia, Ana, Sobrero, Alberto · 2011 · Investigational New Drugs

Abstract

PURPOSE: This phase II, open-label, multicenter study assessed the oral, multitargeted, tyrosine kinase inhibitor sunitinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma who had received prior chemotherapy. EXPERIMENTAL DESIGN: Patients received sunitinib 50 mg/day on Schedule 4/2 (4 weeks on treatment, followed by 2 weeks off treatment). The primary endpoint was objective response rate; secondary endpoints included clinical benefit rate, duration of response, progression-free survival (PFS), overall survival (OS), pharmacokinetics, pharmacodynamics, safety and tolerability, and quality of life. RESULTS: Of 78 patients enrolled, most had gastric adenocarcinoma (93.6%) and metastatic disease (93.6%). All were evaluable for safety and efficacy. Two patients (2.6%) had partial responses and 25 patients (32.1%) had a best response of stable disease for ≥6 weeks. Median PFS was 2.3 months (95% confidence interval [CI], 1.6-2.6 months) and median OS was 6.8 months (95% CI, 4.4-9.6 months). Grade ≥ 3 thrombocytopenia and neutropenia were reported in 34.6% and 29.4% of patients, respectively, and the most common non-hematologic adverse events were fatigue, anorexia, nausea, diarrhea, and stomatitis. Pharmacokinetics of sunitinib and its active metabolite were consistent with previous reports. There were no marked associations between baseline soluble protein levels, or changes from baseline, and measures of clinical outcome. CONCLUSIONS: The progression-delaying effect and manageable toxicity observed with sunitinib in this study suggest that although single-agent sunitinib has insufficient clinical value as second-line treatment for advanced gastric cancer, its role in combination with chemotherapy merits further study.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s10637-010-9438-y

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 193

Metadata

Authors
Bang, Y.-J., Kang, Y.-K., Kang, W. K., Boku, N., Chung, H. C., Chen, J.-S., Doi, T., Sun, Y., Shen, L., Qin, S., Ng, W.-T., Tursi, J. M., Lechuga, M. J., Lu, D. R., Ruiz-Garcia, A., & Sobrero, A.
Venue
Investigational New Drugs
Published
2010-05-12
Volume
29
Issue
6
Pages
1449-1458
ISSN
  • 0167-6997 (ISSN-L)
  • 1573-0646
OpenAlex
W2057988063
Cited by
193
References
3
FWCI
13.53
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase II study of sunitinib as second-line treatment for advanced gastric cancer. https://app.cochat.ai/papers/10.1007/s10637-010-9438-y
The paper
Bang, Y.-J., Kang, Y.-K., Kang, W. K., Boku, N., Chung, H. C., Chen, J.-S., Doi, T., Sun, Y., Shen, L., Qin, S., Ng, W.-T., Tursi, J. M., Lechuga, M. J., Lu, D. R., Ruiz-Garcia, A., & Sobrero, A. (2011). Phase II study of sunitinib as second-line treatment for advanced gastric cancer. Investigational New Drugs. https://doi.org/10.1007/s10637-010-9438-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.